Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Tiffany Avery"'
Publikováno v:
Cancer Research. 81:PS9-63
Background: Biosimilars for trastuzumab were introduced into the US market for the treatment of HER2-positive breast cancer in 2019, with the goal of providing the clinical benefit of the brand product at a lower price (increased value). Adoption of
Autor:
W. Gregory Hundley, Heidi D. Klepin, Marcelo A. Lopetegui, Zanetta S. Lamar, Karen M. Winkfield, Aimee K. Johnson, Kathryn E. Weaver, Randi E. Foraker, Tiffany Avery, Nicholas M. Pajewski, Eleanor C. Davidson, Emily V. Dressler, Brian J. Wells
Publikováno v:
JMIR Cancer, Vol 7, Iss 1, p e18396 (2021)
JMIR Cancer
JMIR Cancer
Background Cardiovascular health is of increasing concern to breast cancer survivors and their health care providers, as many survivors are more likely to die from cardiovascular disease than cancer. Implementing clinical decision support tools to ad
Autor:
Flemming Forsberg, Anush Sridharan, Tiffany Avery, Maria Stanczak, Juan P. Palazzo, Kibo Nam, John R. Eisenbrey, Adam C. Berger
Publikováno v:
Radiology. 285:53-62
Purpose To determine whether three-dimensional subharmonic aided pressure estimation (SHAPE) and subharmonic imaging can help predict the response of breast cancer to neoadjuvant chemotherapy. Materials and Methods In this HIPAA-compliant prospective
Autor:
Susan A. Melin, Mary C. Schroeder, MM Howard-McNatt, Tiffany Avery, Sean F. Altekruse, Alexandra Thomas
Publikováno v:
Cancer Research. 77:P5-10
Introduction: African Americans (AA) present more frequently with triple negative breast cancer (TN) and other aggressive breast cancer subtypes. Invasive lobular (ILC) breast cancer most commonly presents as estrogen receptor (ER)+, progesterone rec
Autor:
Adam C. Berger, R. Anne, Rebecca Jaslow, Frances Guiles, Jocelyn Sendecki, Tiffany Avery, Angela Toss, Massimo Cristofanilli, Melissa Lazar, Juan P. Palazzo, Nicole L. Simone, Theodore N. Tsangaris
Publikováno v:
The Breast. 29:223-230
The primary aim in the management of DCIS is the prevention of recurrence and contralateral tumor. Risk factors for DCIS recurrence and appropriate treatments are still widely debated. Adjuvant therapies after surgical resection reduce recurrences an
Autor:
Melissa DiCarlo, Patricia K. Bradley, Lorraine T. Dean, Andrea M. Barsevick, Tiffany Avery, Amy Leader, Sarah E. Hegarty
Publikováno v:
Supportive Care in Cancer. 24:4979-4986
African American breast cancer survivors (AABCS) have a lower survival rate across all disease stages (79 %) compared with White survivors (92 %) and often have more aggressive forms of breast cancer requiring multimodality treatment, so they could e
Autor:
Massimo Cristofanilli, Tiffany Avery, Allison Zibelli, Frederick M. Fellin, Rebecca Jaslow, A Basu-Mallick
Publikováno v:
Cancer Research. 76:P4-13
Inflammatory breast carcinoma (IBC) is the most aggressive form of breast cancer. The hallmark of IBC is regional extension into dermal lymphatics as tumor emboli causing breast edema and erythema. Pathologic characteristics of IBC include high grade
Autor:
Massimo Cristofanilli, Tiffany Avery
Publikováno v:
Current Breast Cancer Reports. 6:245-250
Inflammatory breast cancer (IBC) is the most aggressive type of breast cancer with survival rates far lower than other types of breast cancer. Patterns of development, invasion, and presentation are unique to IBC compared with other breast cancers. H
Autor:
Zhong Ye, Yinzhi Lai, Terry Hyslop, Bingshan Li, Massimo Cristofanilli, Jinliang Xing, Hushan Yang, Juan P. Palazzo, Tiffany Avery, Jesse Civan, Ronald E. Myers
Publikováno v:
Breast Cancer Research and Treatment. 148:175-185
The use of erythropoiesis stimulating agents (ESAs) to treat anemia in breast cancer patients who are treated with chemotherapy is a matter of ongoing debate. Several recent randomized trials challenged conventional wisdom, which holds that ESAs are
Publikováno v:
The Breast Journal. 19:431-434
The aim of this study was to evaluate the association of bone mineral density (BMD) at the time of diagnosis with clinical-pathologic findings in patients with operable postmenopausal breast cancer. One hundred and fifty-eight postmenopausal women wh